CMS NCD 241 Updated: What Billing Teams Need to Know About Incontinence Control Device Coverage

CMS has modified National Coverage Determination (NCD) 241, which governs Medicare coverage for incontinence control devices—including mechanical/hydraulic devices and collagen implants used to treat urinary incontinence. The Centers for Medicare & Medicaid Services updated this policy effective March 12, 2026, and urology, urogynecology, and general surgery billing teams should review the coverage criteria carefully to ensure claims are submitted with appropriate documentation. Understanding exactly who qualifies under NCD 241 is essential to avoiding denials on what are already complex procedural claims.

Field	Detail
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	Incontinence Control Devices
Policy Code	NCD 241
Change Type	Modified
Effective Date	2026-03-12
Impact Level	Medium
Specialties Affected	Urology, Urogynecology, General Surgery, Colorectal Surgery
Key Action	Audit your documentation workflows for ISD diagnosis and collagen implant pre-treatment evaluation to confirm compliance with NCD 241's updated criteria before March 2026.

---

CMS NCD 241: What This Policy Covers and Why It Matters

NCD 241 falls under the Medicare benefit category of Prosthetic Devices, which is an important designation for billing purposes. Coverage is split across two distinct device types—mechanical/hydraulic incontinence control devices and collagen implants—and each comes with its own set of medical necessity criteria.

This distinction matters because the two categories have fundamentally different documentation requirements, different patient populations, and different thresholds for continued coverage. A billing team that conflates them is setting up for denials.

---

Mechanical/Hydraulic Incontinence Control Devices: CMS Coverage Criteria

Mechanical and hydraulic incontinence control devices work by compressing the urethra to achieve urinary control. CMS recognizes this class of devices as safe and effective for patients with permanent anatomic and neurologic dysfunction of the bladder.

Coverage is available when the device is considered reasonable and necessary for the individual patient. That's a familiar phrase in Medicare policy, but it carries real weight here: the patient's condition must be documented as permanent, not transient or reversible. If your documentation doesn't establish the permanence of the dysfunction, expect a medical necessity challenge.

---

Collagen Implant Coverage Under NCD 241: Who Qualifies

The collagen implant section of NCD 241 is more detailed—and more restrictive. A collagen implant is a prosthetic device injected into the submucosal tissues of the urethra and/or the bladder neck to treat stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD). ISD is the specific clinical diagnosis required; generalized stress urinary incontinence does not qualify on its own.

CMS covers collagen implants only for the following patient types:

• Male or female patients with congenital sphincter weakness secondary to conditions such as myelomeningocele or epispadias
• Male or female patients with acquired sphincter weakness secondary to spinal cord lesions
• Male patients following trauma, including prostatectomy and/or radiation
• Female patients without urethral hypermobility and with abdominal leak point pressures (ALLP) of 100 cm H₂O or less

That last criterion is critical for female patients. An ALLP of less than 100 cm H₂O establishes the ISD diagnosis. If this measurement isn't documented in the record, the claim is vulnerable.

---

Pre-Treatment Evaluation Requirements for Collagen Implants

CMS requires specific pre-treatment evaluation steps before a collagen implant can be covered. These aren't optional workup items—they're coverage prerequisites.

For all patients: A skin test for collagen sensitivity must be administered and evaluated over a four-week period before treatment begins. Skipping this step or failing to document it is a direct path to denial.

For male patients, the evaluation must include:

• Complete history and physical examination
• Simple cystometrogram confirming the bladder fills and stores properly
• Upright stress test (patient standing with a full bladder, asked to cough or apply abdominal pressure) to establish ISD diagnosis

For female patients, the evaluation must include:

• Complete history and physical examination, including pelvic exam
• Simple cystometrogram to rule out abnormalities of bladder compliance and urethral support
• Abdominal leak point pressure (ALLP) test with the bladder filled with a minimum of 150 cc of fluid

Each of these components must appear in the medical record before the implant claim is submitted. Missing any single element creates a documentation gap that payers will exploit on audit.

---

Physician Qualification Requirements for Collagen Implant Procedures

CMS also places requirements on the physician performing the collagen implant procedure—not just the patient's eligibility. To perform a covered collagen implant:

• The physician must have urology training in the use of a cystoscope
• The physician must have completed a collagen implant training program

This is a qualification that needs to be confirmed at the practice level before the first claim goes out. If a physician performs this procedure without meeting both requirements, the claim will not be covered under NCD 241—and that creates potential overpayment liability if it's caught on retrospective review.

---

Coverage Limits on Collagen Implant Sessions

NCD 241 sets a clear ceiling on covered treatment sessions. Patients who do not improve after five injection procedures (five separate treatment sessions) are classified as treatment failures. No further collagen implant treatment for urinary incontinence is covered after that threshold.

However, the policy does allow for some flexibility in cases of recurrence. Patients who previously responded to collagen implant treatment and then experienced a return of incontinence—typically six to 12 months later—may be eligible for additional sessions. But those additional sessions must be supported by documented medical justification. "Patient reports symptoms returned" is not sufficient; the clinical record needs to support the medical necessity of resuming treatment.

Billing teams should build a tracking mechanism for session counts on collagen implant patients. Submitting a claim for a sixth session without documented justification for a recurrence case is a denial waiting to happen.

---

Affected Codes

The current version of NCD 241 does not list specific CPT or HCPCS codes. Billing teams should reference the Medicare Benefit Policy Manual, Chapter 15 for claims processing instructions and consult their MAC's local guidance for applicable procedure codes related to incontinence control devices and collagen implant injections.

Because codes are not enumerated in the NCD, accurate code selection depends on the specific device and procedure performed. Work with your coding team and MAC to confirm the correct HCPCS or CPT codes before submitting claims under this policy.

---

What Your Billing Team Should Do

Copy Action Items

---